Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
18/03/2026 11:57
March 18 (Reuters) - InflaRx NV IF0G.F: INFLARX ANNOUNCES LATE-BREAKER ORAL PRESENTATION ON VILOBELIMAB PHASE 3 RESULTS IN PYODERMA GANGRENOSUM AT 2026 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING Source text: ID:nGNX80jtZY Further company coverage: IF0G.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum